Addendum to Commission A13-10 (Pertuzumab) [Internet].

On 6 August 2013 the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A13-10 (benefit assessment of pertuzumab).

http://ift.tt/2siQifX